Kerri FitzgeraldMantle Cell Lymphoma | February 1, 2023
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Read More
Kerri FitzgeraldMyelodysplastic Syndromes | November 15, 2022
A study showed "unexpected" results related to race and MDS survival...
Kerri FitzgeraldAcute Myeloid Leukemia | February 3, 2023
The efficacy of enasidenib in patients with AML depends on the mutation type.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 5, 2022
The addition of brentuximab vedotin improved survival in Hodgkin lymphoma.
Cecilia BrownAggressive B-Cell Lymphoma | November 22, 2022
A new model that makes use of a promising imaging biomarker can predict diffuse large B-cell lymphoma relapse and survival ...
Leah SherwoodAcute Myeloid Leukemia | February 2, 2023
The expression patterns and clinical significances of CD300s in cancers are still not well understood.
Editorial Board